Ibuprofene doc - pain medication 12 coated tablets

Hepatic impairment In patients with mild or moderate reduction in liver function, the dosage should be kept as low as possible for the shortest duration necessary to control symptoms, and liver function should be monitored. Ibuprofen DOC is contraindicated in patients with severe hepatic impairment (see section 4.3).

Oral administration. To obtain a more rapid onset of action, the dose can be taken on an empty stomach. In patients with gastric sensitivity, it is recommended to take Ibuprofen DOC with food. Take Ibuprofen DOC with a glass of water. To avoid oral discomfort and throat irritation, the tablets should be swallowed whole and should not be chewed, broken, crushed, or sucked. Undesirable effects may be minimised by using the lowest effective dose for the shortest duration necessary to control symptoms (see section 4.4).

Pregnancy and breastfeeding

Pregnancy Inhibition of prostaglandin synthesis may adversely affect the pregnancy and/or embryo/foetal development. Results of epidemiological studies suggest an increased risk of miscarriage, cardiac malformation, and gastroschisis after use of a prostaglandin synthesis inhibitor in early pregnancy. The absolute risk of cardiac malformations increased from less than 1%, up to approximately 1.5%. The risk is believed to increase with dose and duration of therapy. In animals, administration of prostaglandin synthesis inhibitors has been shown to result in increased pre- and post-implantation loss and embryo/foetal lethality. Furthermore, an increased incidence of various malformations, including cardiovascular, has been reported in animals given prostaglandin synthesis inhibitors during the organogenetic period. During the first and second trimesters of pregnancy, Ibuprofen should not be administered unless clearly necessary. If Ibuprofen is used by a woman attempting to conceive or during the first and second trimesters of pregnancy, the dose and duration of treatment should be kept as low as possible. During the third trimester of pregnancy, all prostaglandin synthesis inhibitors may expose the fetus to: – Cardiopulmonary toxicity (with premature closure of the ductus arteriosus and pulmonary hypertension); – Renal dysfunction, which may progress to renal failure with oligo-hydroamniosis; the mother and the newborn, at the end of pregnancy, to: – Possible prolongation of bleeding time, and antiplatelet effect which may occur even at very low doses; - Inhibition of uterine contractions resulting in delayed or prolonged labor. Consequently, IBUPROFENE DOC is contraindicated during the third trimester of pregnancy.

Breastfeeding In the few studies available to date, NSAIDs can be found in breast milk in very low concentrations. NSAIDs, if possible, should be avoided during breastfeeding.

Fertility The use of Ibuprofen may impair female fertility by affecting ovulation and is not recommended in women attempting to conceive. In women who have difficulties conceiving or who are undergoing investigation of infertility, discontinuation of ibuprofen treatment should be considered.

Format

12 coated tablets